Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593450 · ClinicalTrials.gov registry record · Phase 3
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
A Phase 3 study of Age-related Macular Degeneration, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,208
- Enrollment target
- 20
- Study locations
NCT00593450: Completed Phase 3 study of Age-related Macular Degeneration, sponsored by University of Pennsylvania.
NCT00593450 is a Phase 3 study of Age-related Macular Degeneration that has completed, run by University of Pennsylvania. The registered enrollment target is 1,208 participants, below the 1,491-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593450, a Phase 3 study of Age-related Macular Degeneration, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,208 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule. A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.
Primary Outcome
Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline. In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.
Conditions Studied
Interventions
- DRUG bevacizumab
- DRUG ranibizumab
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills
- University of California-Davis Medical Center - Sacramento
- Retinal Consultants Medical Group, Inc. - Sacramento
- West Coast Retina Medical Group, Inc. - San Francisco
- California Retinal Consultants - Santa Barbara
- West Coast Retina Medical Group, Inc. - Walnut Creek
Arizona
- Retina Consultants of Arizona - Mesa
- Retinal Consultants of Arizona - Phoenix
- Retina Associates Southwest, P.C. - Tucson
Illinois
- Illinois Retina Associates - Flossmoor
- Ingalls Memorial Hospital/Illinois Retina Associates - Harvey
- Illinois Retina Associates - Joliet
Florida
- Retina Group of Florida - Fort Lauderdale
- National Ophthalmic Research Institute - Fort Myers
Colorado
- Colorado Retina Associates - Denver
Georgia
- Emory Eye Center - Atlanta
Indiana
- Midwest Eye Institute - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT00593450 record still lists
NCT00593450 is an interventional study that assigns participants to a tested intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus, below the 1,491-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.
NCT00593450 names 20 study sites across 9 states, led by California, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT00593450 about?
NCT00593450 is a clinical study titled "Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial". The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule. A five year follow-up visit is being conducted in 2014 to gat...
What is the current status of trial NCT00593450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,208 participants. The study started on 2008-02. Estimated completion is 2015-04.
What conditions does trial NCT00593450 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT00593450?
The interventions under investigation include: bevacizumab (DRUG), ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00593450?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00593450 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00593450's enrollment target sits among peer trials
1,208 4th of 74 higher than 71 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
-
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
COMPLETED · Phase 3
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia